Published 19 October 2020
This week EATRIS signed a Memorandum of Understanding with the Critical Path Institute (C-PATH) to accelerate drug development for rare diseases by increasing the efficiency of translation of potential therapeutics through preclinical and clinical development.
C-PATH are co-hosting a virtual event on 19th Oct with NORD about the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP). It will be a great chance to hear more about RDCA-DAP, learn about how the platform works and hear case studies on how sharing patient-level data accelerates understanding of rare diseases. Find out more here.
